Biogen and Sage’s Zurzuvae for postpartum depression now available in the U.S.

Biogen (BIIB) and Sage Therapeutics (SAGE) announced Zurzuvae – zuranolone – 50 mg CIV is now available by prescription for the treatment of postpartum depression – PPD – for adults in the U.S., with product already at specialty pharmacies and delivered to patients. Biogen and Sage are prioritizing access through active discussions with national, regional and government payors to advocate for broad and equitable access to Zurzuvae for women with PPD with minimal restrictions. The companies also launched a patient support program, Zurzuvae For You. The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients. The companies are partnering with several of the national specialty pharmacies and Zurzuvae will be shipped directly to women with PPD who are prescribed the treatment.